NEW YORK, Feb. 21, 2020 /PRNewswire/ -- Synapse
Medical Communications (Synapse), a leader in analytics-driven
commercialization solutions, announced that its
"AZOncologyID" website has been named the Gold winner of the
2019 PM360 Pharma Choice Awards, in the Professional
Website category, and its "BiomARker Experience Augmented
Reality" application has been named the Bronze winner in the
Application category.
Synapse developed the Gold Award-winning website
AZOncologyID.com to deliver solutions for the common problems
oncologists face that can delay or completely derail the biomarker
testing process. Combining extensive research and expert insights
around relevant biomarkers for a variety of tumor types,
AZOncologyID has been an overwhelming success, as evidenced by the
almost 30,000 visitors to the site since its launch, elevating it
to become one of the top 5 most visited AstraZeneca websites.
"Due to segmentation of knowledge across sources, many HCPs find
it difficult to keep track of current best practices and crucial
information for the treatment of cancer," said Synapse EVP of
Account Services, Stephanie Jenkins.
"AZOncologyID helps physicians stay up-to-date to ensure that
patients are receiving the best possible treatments."
Winning the Bronze Award, the "BiomARker Experience Augmented
Reality" was developed for AstraZeneca Oncology to guide physicians
through the biomarker testing journey and highlight solutions to
common testing obstacles. The application was featured at 6
professional congresses, engaging thousands of healthcare
professionals and facilitating self-guided interactions.
"Precision medicine is a powerful tool in the fight against
cancer, but full utilization can be stymied by delayed, incomplete,
or inaccurate biomarker testing," said Synapse EVP of Account
Services, Stephanie Jenkins. "To
encourage physicians to optimize the biomarker testing process, and
ultimately allow more patients to receive the best treatment
possible, we created an engagement that uses augmented reality to
review the biomarker testing journey for different tumor types and
provide actionable insights in a unique, interactive manner."
Since 2009, the PM360 Pharma Choice awards has served as
the only industry awards to recognize outstanding achievement and
creativity in healthcare marketing by allowing the industry as a
whole to choose the winners. All submissions are placed online
where anyone in the industry can vote for their favorites based on
content, format, imagination, influence on the industry, and
overall quality. More than 7,000 votes total were cast to decide
this year's winners
"By giving the power of the vote to choose the winners to the
healthcare industry as a whole, we are allowing every person who
has dedicated their career to developing great healthcare creative
to decide what great healthcare creative truly looked like in
2019," says Anna Stashower, CEO and
Publisher of PM360. "In the end, that means all of this
year's winners were able to capture the attention and admiration of
a majority of their peers, which is a worthy achievement in and of
itself."
The winning work is featured in the January/February 2020 issue of PM360 and can be viewed
online at
www.pm360online.com/2019-pm360-pharma-choice-award-winners.
About Synapse Medical Communications
Synapse is a
leading analytics-driven medical communications and
commercialization solutions provider that integrates data science
with medical expertise, creative vision, strategic insights, and
digital execution to maximize the clinical and commercial potential
of our clients' brands at all stages of product developmentāfrom
prelaunch through launch and beyond. Visit Synapse online at:
https://www.synapseny.com/
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synapse-receives-gold-and-bronze-in-2019-pm360-pharma-choice-awards-301009395.html
SOURCE Synapse Medical Communications